Israel’s Immunai could be the secret weapon to faster drug approvals

An American-Israeli immunomics company has announced another success in supporting a major pharmaceutical company in moving its drugs from the lab to clinical approval, The Jerusalem Post has learned. “With our partners, we have succeeded in meeting agreed-upon deliverables,” said Noam Solomon, CEO of Immunai. “In the past two years, we have had a handful […]

Continue Reading